Human Umbilical Cord Mesenchymal Stem Cell(Qilu Cell Therapy)

The main purpose of Phase Ia is to evaluate and determine the safety and tolerability of single-dose treatment for patients with acute-on-chronic liver failure. Secondary purpose: To evaluate the preliminary effectiveness of single-dose treatment for patients with acute-on-chronic liver failure; to provide a basis for the design of subsequent clinical trial doses. Exploratory study objectives: To explore the changes in HGF in patients with acute-on-chronic liver failure after single-dose treatment; to explore the changes in T lymphocyte typing in patients with acute-on-chronic liver failure after single-dose treatment; to explore the changes in humoral immune function in patients with acute-on-chronic liver failure after single-dose treatment. The main purpose of Phase Ib is to evaluate and determine the safety and tolerability of multiple-dose treatment for patients with acute-on-chronic liver failure. Secondary purpose: To evaluate the preliminary effectiveness of multiple-dose treatment for patients with acute-on-chronic liver failure; to provide a basis for the design of subsequent clinical trial doses. Exploratory study objectives: To explore the changes in HGF in patients with acute-on-chronic liver failure after multiple-dose treatment; to explore the changes in T lymphocyte typing in patients with acute-on-chronic liver failure after multiple-dose treatment; to explore the changes in humoral immune function in patients with acute-on-chronic liver failure after multiple-dose treatment. The main purpose of Phase II is to evaluate the preliminary effectiveness of treating patients with acute-on-chronic liver failure. Secondary study objective: To evaluate and determine the safety and tolerability of the treatment of patients with acute-on-chronic liver failure.